Now showing items 1-2 of 2

    • Advances in the treatment of gastrointestinal stromal tumours. 

      Judson, I; Demetri, G (2007-09)
      Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time and delaying disease ...
    • Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. 

      Lankheet, NAG; Desar, IME; Mulder, SF; Burger, DM; Kweekel, DM; van Herpen, CML; van der Graaf, WTA; van Erp, NP (2017-10)
      AIM:Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been established, ...